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Studies on Cadmium-Induced Inhibition
of Hepatic Microsomal Drug
Biotransformation in the Rat
by R. C. Schnell,* J. R. Means,* S. A. Roberts,*
and D. H. Pence*
Cadmium is a potent inhibitor of hepatic microsomal drug biotransformation in the rat. Male rats
receiving a single intraperitoneal dose of cadmium exhibit significant decreases in hepatic microsomal
metabolism ofa variety ofsubstrates. The threshold cadmium dose is 0.84 mg Cd/kg, and the effect lasts
at least 28 days. Mechanistically, the inhibitory effect results from decreased cytochrome P450 content
since cadmium does not alter NADPH cytochrome c reductase activity. This effect is also observed
following acute oral administration of cadmium in doses greater than 80 mg Cd/kg but is not observed
following chronic administration of the metal via drinking water in concentrations of 5-200 ppm for
periods ranging from 2 to 50 weeks. A tolerance to the inhibitory cadmium effect is observed ifmale rats
are pretreated with subthreshold doses of the metal prior to the challenge cadmium dose. The degree of
tolerance can be overcome by increasing thechallenge dose ofcadmium. Characterization ofthe tolerance
phenomenon in terms of onset, duration, and intensity reveals a good correlation with the kinetics of
metaliothionein production, suggesting that the underlying basis for the tolerance phenomenon is likely
the induction of metallothionein. A sex-related difference in the inhibitory effect of cadmium was ob-
served. Cadmium did not inhibit the metabolism ofhexobarbital or ethylmorphine in female rats but did
inhibit that ofaniline orzoxazolamine. Cadmium did not lowercytochrome P-450content in female rats.
Introduction
Within the last decade, several investigators have
found that many ofthe heavy metals, considered to
be environmental pollutants, possess the ability to
inhibit the hepatic microsomal enzyme system re-
sponsible for the biotransformation of hormones,
drugs, and xenobiotics. This may be ofconsiderable
importance since alterations in this enzyme system
could alter the toxic potential of a wide variety of
other substances with which the biological system
comes into contact.
Our laboratory has been engaged in studying the
toxicity of cadmium with particular interest in the
effect of this metal on the mixed-function oxidase
system (I) located in hepatic microsomes since this
heavy metal accumulates in rather high concentra-
tions in the liver and induces hepatotoxicity. This
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communication describes various studies con-
cerned with the inhibitory effects ofcadmium on the
hepatic microsomal drug metabolizing system in
rats.
Materials and Methods
Male Sprague-Dawley derived rats (Laboratory
Supply Co., Indianapolis) were used throughout
these studies. The animals were housed in commu-
nity cages for 10-14 days in air-conditioned rooms
with controlled light-dark cycles (12:12) and free
access to food and water.
Cadmium acetate (Fischer Scientific Co., Fair
Lawn, N. J.) was administered in varying doses by
parenteral or oral routes or in the drinking water.
Controls received sodium acetate (NaAc) in such a
dose or concentration as to receive acetate ion
equimolar to the acetate concentration in the cad-
mium solutions.
Hexobarbital (100 mg/kg, IP) hypnosis was mea-
sured as the time elapsing between the loss and re-
273gaining of the righting reflex. Hepatic drug metab-
olism of various substrates was measured using the
105,000g,a, microsomal pellet as previously de-
scribed (2, 3). Substrates used were: hexobarbital,
determined by the method of Brodie et al. (4);
ethylmorphine, assessed by determining the amount
offormaldehyde formed using a modification ofthe
method of Nash (5) as described by Anders and
Mannering (6); and aniline, determined by the
method of Imai et al. (7). Unless stated otherwise
enzyme activity was expressed as: hexobarbital,
nmoles hexobarbital metabolized/mg microsomal
protein/20 min; ethylmorphine, nmoles formal-
dehyde formed/mg microsomal protein/15 min; and
aniline nmole p-aminophenol formed/mg micro-
somal protein/20 min. Cytochrome P-450 content in
microsomes was estimated by the method ofOmura
and Sato (8). Hepatic metallothionein concentra-
tions in the 105,000gmax supernatant were measured
by the method of Probst et al. (9), which measures
metallothionein and total cadmium binding capacity
of the metallothionein.
The data were analyzed statistically by use of
analysis of variance followed by application of
Newman-Keuls test where appropriate or by use of
Dunnett's multiple comparisons test (10).
Results and Discussion
Inhibition of Hepatic Microsomal Drug
Metabolism by Cadmium
Following the parenteral administration of cad-
mium in doses ranging from 0.84 to 2.30 mg /Cd/kg,
male rats exhibit significantly prolonged responses
to drugs (1-3, 11) consequent to a significant inhibi-
tion of hepatic microsomal metabolism of a wide
variety of substrates (1-3, 11-14). Dose-response
studies indicate that the threshold dose for this ef-
fect is 0.84 mg Cd/kg, by the intraperitoneal route
(11). Interestingly, doses of cadmium greater than
this dose do not produce any greater inhibition of
this enzyme system. As shown in Figure 1, the
magnitude ofinhibition for each ofthree substrates,
hexobarbital, ethylmorphine, or aniline, did not
differ when comparing cadmium doses of 0.84 and
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FIGURE 1. Effect of varying doses of intraperitoneally adminis-
tered drug metabolism in the rat. Metabolism assays were
conducted 72 hr after cadmium treatment. Asterisks (*) de-
note values significantly different from control (p < 0.05).
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FIGURE 2. Duration of inhibition of hepatic microsomal drug
metabolism following cadmium (0.84 mg Cd/kg, IP) adminis-
tration. Asterisks (*) denote values significantly different
from control (p < 0.05).
Table 1. Effect of cadmium on enzyme activity and cytochrome P-450 content in male rat hepatic microsomes.
Microsomal enzyme activity
Per Per Cytochrome P-450,
(mg microsomal protein)/20 min (nmole cytochrome P-450)/20 min nmole/mg microsomal protein
Measurement NaAc CdAc % Change NaAc CdAc % Change NaAc CdAc % Change
Substrate
Hexobarbital 266 ± 15 55 ± 6 -79 209 ± 12 72 + 8b -65
Ethylmorphine 347 ± 17 100 + 4b -71 272 ± 13 131 ± 5b -52
Aniline 31 ± 1 17 llb -47 25 ± 1 22 + 1 -11 1.25 ± 0.04 0.76 ± 0.02b -39
a Male rats received cadmium (2.0 mg Cd/kg, IP) and 72 hr later measurement of hepatic drug metabolism, spectral binding, or
cytochrome P-450 content was conducted. From Means et al. (15).
b Significantly different from control (p < 0.05).
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2742.0 mg Cd/kg (IP). However, differences were ob-
served in the amount of inhibition when the sub-
strates were compared. Similar results were found
when hexobarbital hypnosis was used in that doses
of cadmium between 0.84 and 2.5 mg Cd/kg, (IP)
produced about the same degree of potentiation of
duration of hypnosis (1, 11).
The duration of the inhibitory effect of cadmium
has been reported to vary. Most experiments were
of short duration of less than 7 days. Hadley et al.
(2) reported that cadmium potentiated duration of
hexobarbital hypnosis for 10 days, but values had
returned to control levels by 17 days. However, we
have found that a single acute dose of0.84 mg Cd/kg
given by the intraperitoneal route inhibited micro-
somal enzyme activity using three different sub-
strates for at least 28 days, the longest time interval
examined (Fig. 2). As indicated, the magnitude of
inhibition exhibited by cadmium tends to vary with
the substrate used. In this regard, typical results are
presented in Table 1 for hexobarbital, ethylmor-
phine, and aniline as representative examples of
type I (HS, EM) or type II (AN) substrates, respec-
tively. The magnitude of inhibition elicited by cad-
mium treatment was 1.5 to 1.7 times greaterfortype
I substrates than for type II. Cadmium also de-
pressed the level of microsomal cytochrome P-450
content (Table 1) but exerted no significant effect on
NADPH cytochrome c reductase activity (226 + 9
vs. 187 + 36 nmole cytochrome c reduced/mg
protein/min).
From these data, the inhibitory effect ofcadmium
on hepatic microsomal drug metabolism most likely
results from decreasing the availability of the mi-
crosomal hemoprotein, cytochrome P-450. Fur-
thermore, ifthe enzyme activities are expressed on
the basis ofcytochrome P-450 content, microsomal
aniline hydroxylase activity in cadmium-treated rats
was not significantly (11%) altered, while
cadmium-induced inhibition ofthe rate of hexobar-
bital metabolism and ethylmorphine was still sig-
nificant (65% and 52%, respectively) though of
lesser magnitude. Significant decreases (30-40%o) in
microsomal cytochrome P-450 content have been
reported by others (1, 2, 13-15). Additional studies
by Krasny and Holbrook (13) indicate thatcadmium
induces microsomal heme oxygenase (350%), the
first enzyme responsible for heme degradation.
Correlated with the induction ofthis enzyme, there
is an increase in the degradation of cytochrome
P-450 as assessed by measuring the decline of 3H-
8-aminolevulinic acid from microsomal CO-binding
particles (13, 16).
Since the previous studies were concerned with
the parenteral administration of cadmium, we ex-
amined the effect of acute oral cadmium adminis-
tration on drug response and metabolism. The data
shown in Figure 3 indicate that cadmium also effec-
tively potentiates duration ofhexobarbital hypnosis
in a dose-response relationship with the threshold
cadmium dose being 80 mg Cd/kg, and the mag-
nitude of potentiation increasing with increasing
cadmium doses (Fig. 3). Similar results were found
wben cadmium inhibition of microsomal metab-
olism of hexobarbital and aniline was examined
(17).
Thus, following the acute administration of cad-
mium by either parenteral or oral routes, there is a
rather clear threshold dose required to alter hepatic
drug metabolism. Interestingly, the oral/
intraperitoneal dose ratio is about 100/1, a value
which correlates well with the observation that only
1-2% ofan oral cadmium dose is absorbed (18). Our
findings with oral cadmium administration differ
from the data of Kotsonis and Klaassen (19), who
administered cadmium chloride orally in doses
ranging from 0 to 150 mg Cd/kg but found no alter-
ations in microsomal cytochrome P-450 content or
aniline hydroxylase activity at 2 or 4 days after
cadmium. These investigators did find a slight de-
crease in hexobarbital oxidase activity at 2 days but
not 14 days after cadmium. At present, we have no
explanation for these differences in observations.
The effect ofchronic cadmium administration on
hepatic drug metabolism was investigated by giving
cadmium in the drinking water. In the first study,
cadmium was administered in concentrations of
100-200 ppm for periods of 2-12 weeks. From the
data in Table 2, it is readily apparent that there were
no alterations in drug response or hepatic drug me-
tabolism in spite of the observation that the total
cadmium intake was much greater than the acute
oral dose required for altering enzyme activity. In
another study of similar design, rats received cad-
mium in the drinking water at concentrations of5 or
20 ppm for 50 weeks. Again, no changes in drug
response or metabolism were found (17). Similar
results have been reported by Becking (20), who
administered cadmium (to rats) in drinking water at
concentrations of 2-200 ppm for 60-180 days and
found no change in hepatic drug metabolizing activ-
ity or cytochrome P-450 content.
Although no studies have yet been directed to
resolve these differences between the acute and
chronic effects of orally administered cadmium,
they are likely related to cadmium levels reaching
the liver. As indicated, about 1-2% of an oral cad-
mium dose is absorbed (18). In addition, the ability
ofcadmium to induce the cadmium-binding protein,
metallothionein, in various tissues offers a further
complicating factor. Thus, metallothionein induced
in the intestinal mucosa (21) may decrease the ab-
February 1979 275sorption of the metal and metallothionein in the
liver (9) may bind cadmium in an inert form, thus,
preventing toxicity.
Tolerance to the Cadmium-Induced
Inhibitory Effects
Pretreatment of animals with subtoxic doses of
cadmium has been shown to prevent various toxic
syndromes attributed to higher doses of cadmium
(22-26). In our laboratory we have found that if
subthreshold doses of cadmium (0.21 or 0.42 mg
Cd/kg, IP) are administered prior to the threshold
cadmium (0.84 mg Cd/kg, IP) dose, the cadmium-
induced inhibition in drug metabolism is no longer
observed (1, 26). Correlated with this tolerance
phenomenon were increased hepatic concentrations
of metallothionein offering support for the protec-
tive role of this cadmium-binding protein (27). A
series of experiments were conducted to charac-
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FIGURE 3. Effect of varying doses of orally administered cad-
mium on duration of hexobarbital hypnosis. Experiments
were conducted 72 hr after cadmium treatment. Asterisks (*)
denote values significantly different from control (p < 0.05).
terize this tolerance phenomenon with respect to
onset, duration, and level of intensity. The
minimum time period for a subthreshold dose of
cadmium (0.21 mg/kg, IP) to produce a tolerance to
the threshold cadmium dose was 14 hr, and the
phenomenon lasted for at least 336 hr, the longest
time interval measured when either duration of
hexobarbital hypnosis or hepatic drug metabolism
was used (1, 27). The peak intensity ofthe tolerance
occurred at 72 hr. The minimal tolerance producing
dose ofcadmium was 0.1 mg Cd/kg for the challenge
(0.84 mg Cd/kg) cadmium dose (27). We also found
that the intensity oftolerance was finite. In this ex-
periment, the tolerant state was induced by ad-
ministering cadmium (0.21 mg/kg) and 72 hr later
the animals were challenged with cadmium in doses
ranging from 0.84 to 3.2 mg Cd/kg. From Figure 4, it
can be seen that tolerance was no longerapparent in
animals receiving cadmium in doses greaterthan 2.0
mg Cd/kg, when considering the average values for
each cadmium dose. Interestingly, however, when
the individual data points were plotted, it would ap-
pear that there are at least two different populations
of animals per challenge dose, i.e., a group of rats
that were nontolerant and a group of tolerant rats.
The nature of this individual variability is not
known.
The role of metallothionein in this tolerance
phenomenon was assessed by comparing the kinet-
ics of synthesis of the protein with the temporal
development of the tolerance phenomenon. Rats
received cadmium (0.21 mg Cd/kg) and were sac-
rificed at varying intervals thereafter. Total metal-
lothionein concentrations and cadmium-binding
capacity of the protein increased rapidly and were
maximal from 8 to 67 hrbut remained above control
values from 67 to 240 hr, declining thereafter (27).
Thus, these data correlate well with the temporal
development and duration of the tolerance
phenomenon reported in previous experiments.
Table 2. Effect ofchronic oral cadmium administration on duration ofhexobarbital hypnosis and hepatic microsomal drug metabolism in
male rats.a
Duration of hexobarbital Hepatic hexobarbital,
Treatment Duration of treatment, hypnosis, ,umole metabolism
Cd, ppm weeks Total Cd consumed, mg min S. E. mg protein-hr
0 12 0 19.2 ± 1.1 (6) 1.24 ± 0.12 (6)
100 2 43.1 ± 2.3 17.9 ± 1.8 (8) 1.43 ± 0.11 (8)
100 4 89.6 ± 2.5 16.5 0.9(7) 1.13 ± 0.13 (6)
100 12 233.5 ± 19.8 16.4 ± 1.5 (6) 1.04 ± 0.08 (6)
200 2 61.2 ± 3.3 21.7 3.1 (7) 1.10 ± 0.10 (6)
200 4 154.9 ± 77.6 18.2 ± 0.8 (7) 1.12 ± 0.07 (6)
a Adult, male rats were housed individually, and cadmium was administered in the drinking water in the concentrations and for the
time intervals as designated controls received sodium acetate. Hypnosis was induced by hexobarbital (100 mg/kg, IP). Hexobarbital
metabolism was measured in hepatic microsomes as described. Adapted from Schnell et al. (18).
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FIGURE 4. Alteration of cadmium-induced tolerance phenome-
non. Male rats received a tolerance-producing cadmium dose
(0.21 mg Cd/kg, IP) and 3 days later were challenged with
increasing cadmium doses and duration of hexobarbital hyp-
nosis was measured 72 hr later. The data are plotted as indi-
vidual points (filled circles) and as average values (horizontal
bar) ± S.E.M. Asterisks (*) denote values significantly dif-
ferent from control (p < 0.05).
Sex-Related Differences in Cadmium
Inhibition of Hepatic Drug Metabolism
In previous studies we have r<;ported that
cadmium-induced inhibition ofhepatic drug metab-
olism in the rat is sex-related withcadmium exerting
no inhibitory effects in the female (1, 3, 28). Dose-
response studies revealed that lethal doses of cad-
mium were ineffective in potentiating the duration
of hexobarbital hypnosis in female rats (3). These
sex-related differences in the cadmium effect are
apparently substrate-dependent, as shown in Figure
5. When the effect of cadmium on hepatic metab-
olism of hexobarbital, ethylmorphine, aniline, or
zoxazolamine was assessed in male and female rats,
a significant cadmium inhibition in the metabolism
ofall four substrates was observed in the male rats.
In female rats, no inhibition was observed in the
metabolism ofhexobarbital or ethylmorphine; how-
ever, a significant inhibition was elicited by cad-
mium in the metabolism of aniline and zoxa-
zolamine but oflesser magnitude than the inhibition
observed in the males. Hexobarbital, ethylmor-
phine, and zoxazolamine are type I substrates and
the metabolism of hexobarbital and ethylmorphine
show sex-dependent characteristics, while that of
zoxazolamine is sex-independent. Aniline is
characterized as a type II, sex-independent sub-
strate. In additional studies, there was no effect of
cadmium on cytochrome P-450 content in female
rats (29). Since sex-dependent hepatic drug metab-
olism is apparently controlled by the influence of
the male sex hormone, testosterone, on enzyme ac-
tivity (30), it was of interest to determine if these
sex-related differences to cadmium observed in the
rat were androgen sensitive and mediated via
cadmium-induced testicular necrosis (22). In this
experiment the effect of cadmium on hepatic drug
metabolism and drug responses was examined in
castrated male rats. The data presented in Table 3
indicate that cadmium administered to castrated
rats potentiated duration of hexobarbital hypnosis
only 54% compared to 235% in sham-operated
males, and inhibited hepatic metabolism of
hexobarbital only 39%o in castrated rats compared to
75% in controls. With aniline as the substrate, no
inhibition in hepatic drug metabolizing enzyme ac-
tivity was observed in the castrated rats treated
with cadmium. Thus, these results indicate that
castration affords partial protection against
cadmium-induced inhibition ofhepatic drug metab-
olism. In addition, experiments, we have found that
cadmium exerts no inhibitory effects on hepatic
drug metabolism in immature male or female rats
(29).
Conclusion
Cadmium is a potent inhibitor of hepatic micro-
somal drug metabolism in the male rat. The inhibi-
tion results from a decrease in the microsomal con-
tent ofcytochrome P-450. Clear threshold relation-
Table 3. Effect ofcadmium treatment on drug response and hepatic microsomal drug metabolism in castrated male rats.a
Duration of hexobarbital Hepatic microsomal drug metabolism
hypnosis, min ± S.E. Hexobarbital Aniline
Sex NaAc CdAc NaAc CdAc NaAc CdAc
Sham 20.8 ± 1.5 69.7 ± 6.3b 1.06 + 0.06 0.27 + 0.07b 60.4 + 1.4 49.1 ± 4.5b
Castrated 31.6 ± 3.5 48.8 ± 6.1b 0.82 ± 0.05 0.50 ± 0.09" 60.6 ± 2.9 54.7 ± 2.0
a Sham-operated and castrated male rats received cadmium (2 mg/kg, IP) and 72 hr later duration of hexobarbital hypnosis or
microsomal metabolism of hexobarbital or aniline was measured.
b Significantly different from respective control (p < 0.05).
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FIGURE 5. Effect of cadmium on hepatic microsomal drug me-
tabolism in male and female rats. Male orfemale rats received
cadmium (2.0 mg Cd/kg, IP), and hepatic microsomal metab-
olism was measured 72 hr later. Asterisks (*) denote values
significantly different from controls (p < 0.05).
ships have been defined for the inhibitory effects to
be manifested after acute cadmium administration
despite route of administration of the metal. Ad-
ministration of cadmium in doses ineffective to in-
hibit drug metabolism produces a tolerance to the
subsequent administration ofan effective challenge
cadmium dose. The underlying basis of this toler-
ance is probably the induction ofmetallothionein, a
cadmium-binding protein. Chronic administration
ofthe metal in drinking water does not alter hepatic
drug metabolism, probably as a result of metal-
lothionein induction. The inhibitory effect of cad-
mium toward the hepatic microsomal drug
metabolizing enzyme system in the rat shows sex-
related characteristics. Although the metabolism of
all drug substrates is inhibited in male rats, such
inhibition is exhibited in female rats only for those
substrates which are sex-independent in terms of
metabolic rate.
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